Market research
YDO1.F Madrigal Pharmaceuticals, Inc
F EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 9B
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -1.05
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 9B
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- -1.05
About
About Madrigal Pharmaceuticals, Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Research context
Madrigal Pharmaceuticals, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the YDO1.F discussion.
5 years, 6 months ago
Madrigal Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 14.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Madrigal Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 113.1% to $-59M since the same quarter in the previous year.
Finally, its free cash flow fell by 342.6% to $-55M since the same quarter in the previous year.
Based on the above factors, Madrigal Pharmaceuticals, Inc gets an overall score of 1/5.